RxDoctor Payments Data

Carline Lamour-Occean, NP

Adult Health · New York, NYNPI 1952654188

Payments from drug & device makers

$2,683in general payments, 2019–2025

Across 68 payments — averaging $39.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$813
  • E.r. Squibb & Sons, L.L.C.$578
  • Johnson & Johnson$496
  • Otsuka America Pharmaceutical, Inc.$404
  • Teva Pharmaceuticals USA, Inc.$154
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$129
  • plus $108 from 3 others

What the payments were for

  • Food & beverage$2,683100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,683 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$3,665
Medicare patients
14
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole18$47,685
Invega SustennaPaliperidone Palmitate13$25,584
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$3,732
Aripiprazole66$1,613
Bupropion XlBupropion Hcl102$1,064
Zolpidem Tartrate157$973
Clonazepam134$916
Quetiapine Fumarate116$830
Lorazepam23$826
Gabapentin56$740
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$739
Haloperidol Decanoate18$666
Escitalopram Oxalate124$617
Trazodone Hcl79$472
Hydroxyzine Hcl32$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$404$47,68518 claims
Johnson & JohnsonInvega Sustenna$496$25,58413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.

Other adult health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →